Center of Excellence in Translational Human Stem Cell Research, California National Primate Research Center, University of California Davis, Sacramento, CA, 95817, USA.
J Cancer Res Clin Oncol. 2014 Jan;140(1):1-14. doi: 10.1007/s00432-013-1494-1. Epub 2013 Aug 30.
The lethal effects of cancer are associated with the enhanced tumor aggressiveness in recurrent and metastatic lesions that show resistant phenotype to anti-cancer therapy, a major barrier to improving overall survival of cancer patients. The presence of heterogeneous populations of cancer cells within a specific tumor including the tumor-initiating cells or so-called cancer stem cells (CSCs) has linked the acquired resistance (AR, or adaptive resistance). Herein, we discuss the CSC-mediated tumor repopulation in AR of breast cancer in this review.
We emphasize a dynamic feature of gene induction in tumor cells that undergo long-term treatment, and describe a specific HER2-NF-κB-HER2 pro-survival pathway that can be initiated in breast CSCs upon radiation therapy.
Elucidation of HER2-induced pro-survival networks, specifically the force driving tumor repopulation due to radioresistant CSCs during anticancer therapies, will have a significant impact on the generation of new diagnostic and therapeutic targets to control of recurrent and metastatic breast tumors.
癌症的致命效应与复发性和转移性病变中肿瘤侵袭性增强有关,这些病变对癌症治疗表现出耐药表型,这是提高癌症患者总体生存率的主要障碍。在特定肿瘤内存在异质的癌细胞群体,包括肿瘤起始细胞或所谓的癌症干细胞(CSC),与获得性耐药(AR,或适应性耐药)有关。在本文中,我们讨论了 CSC 介导的乳腺癌 AR 中的肿瘤再增殖。
我们强调了肿瘤细胞在长期治疗过程中基因诱导的动态特征,并描述了一个特定的 HER2-NF-κB-HER2 促生存途径,该途径可在放射治疗后乳腺 CSC 中启动。
阐明 HER2 诱导的促生存网络,特别是由于放射抗性 CSC 导致的在抗癌治疗期间肿瘤再增殖的驱动力,将对产生新的诊断和治疗靶点以控制复发性和转移性乳腺肿瘤产生重大影响。